CDX2 - Linking Cell and Patient Fates in Colon Cancer #MMPMID26849302
Fearon ER; Huang EH
Cell Stem Cell 2016[Feb]; 18 (2): 168-9 PMID26849302show ga
Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to poor benefit observed for the population as a whole. Recently, Dalerba et al identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.